Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Assets (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Non-Current Assets for 10 consecutive years, with $143000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 62.76% year-over-year to $143000.0, compared with a TTM value of $143000.0 through Dec 2025, down 62.76%, and an annual FY2025 reading of $143000.0, down 62.76% over the prior year.
  • Other Non-Current Assets was $143000.0 for Q4 2025 at Zevra Therapeutics, down from $153000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 million in Q1 2024 and bottomed at $53000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $389157.9, with a median of $384000.0 recorded in 2024.
  • The sharpest move saw Other Non-Current Assets plummeted 87.9% in 2022, then surged 3269.81% in 2024.
  • Year by year, Other Non-Current Assets stood at $438000.0 in 2021, then tumbled by 87.9% to $53000.0 in 2022, then surged by 77.36% to $94000.0 in 2023, then surged by 308.51% to $384000.0 in 2024, then plummeted by 62.76% to $143000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for ZVRA at $143000.0 in Q4 2025, $153000.0 in Q3 2025, and $220000.0 in Q2 2025.